X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
GSK Pharma Fact Sheet, GSK Pharma Financial Results - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK Pharma Fact Sheet   (GLXO)

Here is the latest financial fact sheet of GSK Pharma. For more details, see the GSK Pharma quarterly results and GSK Pharma share price and chart. For a sector overview, read our pharmaceuticals sector report.

GSK PHARMA Price History

Price Rs 2,445.0
Mkt Cap Rs m 207,092
Vol '000 0.1
P/E X 64.2
P/CF X 57.0
EPS (TTM) Rs 38.1
% ch % -0.5
No. of shares m 84.70
% ch week % -1.0
% ch 1-mth % 0.3
% ch 12-mth % -10.2
52 week H/L Rs 2,795.0/2,309.1
(As on Jan 23, 2018 09:49:00 AM)
* Results Consolidated
Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

GSK PHARMA Financials

No. of Mths
Year Ending
12
Dec-12
12
Dec-13
15
Mar-15
12
Mar-16
12
Mar-17
5-Yr Chart
Click to enlarge
GSK PHARMA EQUITY SHARE DATA
High Rs2,3383,0023,5503,8503,838 
Low Rs1,9162,0052,3522,9662,637 
Sales per share (Unadj.) Rs312.9302.6396.5335.1354.2 
Earnings per share (Unadj.) Rs66.356.955.744.439.8 
Diluted earnings per shareRs66.356.955.744.439.8 
Cash flow per share (Unadj.) Rs68.459.258.747.442.9 
Dividends per share (Unadj.) Rs50.0050.0062.5050.0030.00 
Adj. dividends per shareRs50.0050.0062.5050.0030.00 
Dividend yield (eoy) %2.42.02.11.50.9 
Book value per share (Unadj.) Rs236.9234.9288.6257.8236.9 
Adj. book value per shareRs236.9234.9288.6257.8236.9 
Shares outstanding (eoy) m84.7084.7084.7084.7084.70 
Bonus/Rights/Conversions  ----- 
Price / Sales ratio x6.88.37.410.29.1 
Avg P/E ratio x32.144.053.076.781.4 
P/CF ratio (eoy) x31.142.350.372.075.5 
Price / Book Value ratio x9.010.710.213.213.7 
Dividend payout %75.487.9112.2112.675.4 
Avg Mkt Cap Rs m180,157212,038249,933288,643274,216 
No. of employees `0004.75.04.74.64.7 
Total wages/salary Rs m2,9553,6214,9304,4344,830 
Avg. sales/employee Rs Th5,632.25,090.87,211.76,154.76,387.0 
Avg. wages/employee Rs Th627.9719.31,058.6961.61,028.3 
Avg. net profit/employee Rs Th1,194.0956.91,012.7815.8717.1 
GSK PHARMA INCOME DATA
Net Sales Rs m26,50525,62733,58528,37930,000 
Other income Rs m1,7461,7701,9991,228728 
Total revenues Rs m28,25127,39735,58429,60730,728 
Gross profit Rs m8,2615,2826,2834,7834,190 
Depreciation Rs m178199254250263 
Interest Rs m30000 
Profit before tax Rs m9,8266,8538,0285,7614,655 
Minority Interest Rs m00000 
Prior Period Items Rs m00000 
Extraordinary Inc (Exp) Rs m-1,482262-51923457 
Tax Rs m2,7252,2982,7932,0231,744 
Profit after tax Rs m5,6194,8174,7163,7613,368 
Gross profit margin %31.220.618.716.914.0 
Effective tax rate %27.733.534.835.137.5 
Net profit margin %21.218.814.013.311.2 
GSK PHARMA BALANCE SHEET DATA
Current assets Rs m26,46726,23925,87021,73716,742 
Current liabilities Rs m8,3648,8895,0025,7927,202 
Net working cap to sales %68.367.762.156.231.8 
Current ratio x3.23.05.23.82.3 
Inventory Days Days3949416852 
Debtors Days Days1614111621 
Net fixed assets Rs m1,3321,6202,4444,7778,635 
Share capital Rs m847847847847847 
"Free" reserves Rs m19,20419,03323,59420,98519,222 
Net worth Rs m20,06819,89724,44121,83220,069 
Long term debt Rs m4136261610 
Total assets Rs m30,01731,29532,24430,54930,038 
Interest coverage x3,276.3NMNMNMNM 
Debt to equity ratio x00000 
Sales to assets ratio x0.90.81.00.91.0 
Return on assets %18.715.414.612.311.2 
Return on equity %28.024.219.317.216.8 
Return on capital %41.535.730.726.525.5 
Exports to sales %0.70.40.200 
Imports to sales %8.112.312.914.90 
Exports (fob) Rs m196956340 
Imports (cif) Rs m2,1523,1594,3344,2370 
Fx inflow Rs m715625699519528 
Fx outflow Rs m4,1415,3807,6808,3207,193 
Net fx Rs m-3,426-4,755-6,981-7,801-6,665 
GSK PHARMA CASH FLOW
From Operations Rs m 3,136 2,813 3,409 1,389 2,360 
From Investments Rs m -1,097 1,890 1,776 4,990 3,008 
From Financial Activity Rs m -4,406 -4,941 -4,970 -6,383 -5,108 
Net Cashflow Rs m -2,367 -239 215 -4 260 
* Results Consolidated
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Share Holding

Indian Promoters 0.0%
Foreign collaborators 50.7%
Indian inst/Mut Fund 10.2%
FIIs 23.8%
ADR/GDR 0.0%
Free float 15.4%
Shareholders 102,036
Pledged promoter(s) holding 0.0%
 

Company Information

REGD OFF Dr. Annie Besant Road, Worli, Mumbai - 400 030
E-MAIL ajay.a.nadkarni@gsk.com WEB www.gsk-india.com
TELEPHONE (022) 2495 9415 FAX (022) 2498 1526
SECTOR PHARMACEUTICALS GROUP M N C
TR AGENT Karvy Computershare, 17-24, Vithalrao Nagar, Madhapur, Hyderabad-81
AUDITOR Price Waterhouse & Co.
CHM: D. S. Parekh COMP SEC: A. A. Nadkarni (GM & Admin) YEAR OF INC: 1924 BSE CODE: 500660 FV (Rs): 10 DIV YIELD (%): 1.2

More Pharmaceuticals Company Fact Sheets:   CIPLA  ASTRAZENECA PHARMA  UNICHEM LAB  FDC LTD.  AUROBINDO PHARMA  

Compare GSK PHARMA With:   CIPLA  ASTRAZENECA PHARMA  UNICHEM LAB  FDC LTD.  AUROBINDO PHARMA  

Compare GSK PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Hits 36,000-Mark; Infosys & Tata Steel Top Gainers(09:30 am)

Asian equities are higher today as Chinese and Hong Kong shares show gains. The Shanghai Composite is up 0.82% while the Hang Seng is up 1.26%. The Nikkei 225 is trading up by 0.93%.

Views on news

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

More Views on News

Most Popular

Mutual Funds Clearly Tell Us That There is a Bubble in the Stock Market(Vivek Kaul's Diary)

Jan 11, 2018

The maximum amount of money ever has come into equity mutual funds during the current financial year.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GSK PHARMA

GSK PHARMA - ACTAVIS COMPARISON

COMPARE GSK PHARMA WITH

MARKET STATS